Amylyx Pharmaceuticals, Inc. (AMLX) · Nov 5, 2026 · Earnings
In line — Q3 EPS $0.38 loss vs ~$0.381 consensus
Amylyx’s Q3 earnings matched expectations, while cash climbed sharply to fund avexitide’s planned 2027 launch and NDA filing.
Amylyx is a pre-commercial biotech pivoting around avexitide: its Phase 3 LUCIDITY trial in post-bariatric hypoglycemia has already delivered positive topline data, and the company is preparing an FDA filing by year-end and a potential 2027 launch. That direction was already public before this quarterly release, including the planned NDA timing and launch preparation.
The quarter itself was essentially in line, not a fresh earnings surprise. Amylyx posted a $0.38 quarterly loss per share versus a published consensus of roughly $0.381, while the prior-year loss was $0.37. The filing gives no meaningful commercial revenue signal; this remains a development-stage company funding trials and pre-launch infrastructure.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss per share (Income Statement) | $0.38 loss | $0.37 loss | $0.381 loss |
| R&D expense (Financial Results) | $28.4M | $19.9M | |
| SG&A expense (Financial Results) | $21.3M | $16.2M | |
| Cash, equivalents and securities (Cash Position) | $768.1M |
The meaningful business change is financial capacity, but it was already disclosed. Cash and marketable securities reached $768.1 million after the August equity offering, whose roughly $544.6 million of net proceeds were previously announced. The added capital materially reduces near-term financing pressure as Amylyx builds commercial capabilities, but it is not new information at this filing date. The August offering was explicitly intended to support a potential avexitide launch and related development spending.
The clinical story remains strong, but this release mostly repeats the prior catalyst. LUCIDITY met its prespecified primary endpoint with a 55% reduction in composite Level 2 and Level 3 hypoglycemic events versus placebo, and all secondary endpoints were met. 〔0〕 That is the central reason Amylyx has moved from a trial-stage narrative toward regulatory and commercial execution—but the topline result was already reported in August, so this 8-K does not materially reset expectations.
Spending is rising because Amylyx is moving toward launch. R&D increased to $28.4 million as LUCIDITY and avexitide work advanced, while SG&A rose to $21.3 million as the company hired across marketing, market access, patient services, and commercial operations. 〔1〕 The burn is therefore consistent with the stated transition, not evidence of a new operating setback.
Bottom line: This is a confirmation quarter: earnings were in line, the balance sheet is well funded, and avexitide remains on its planned regulatory path. It matters as execution support for the launch story, but it does not add a new surprise beyond the already-public trial result and financing.
NDA submission by year-end; LUCIDITY presentation November 15
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!